Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Markets Market Views

Pfizer’s COVID-19 vaccines expected to generate $15 billion in 2021

Olumide Adesina by Olumide Adesina
February 2, 2021
in Market Views, Stock Market
Pfizer’s COVID-19 vaccines expected to generate $15 billion in 2021
Share on FacebookShare on TwitterShare on Linkedin

The world’s leading drug maker, Pfizer, has issued a mixed earnings report on its fourth quarter of the 2020 fiscal year that slightly missed stock experts’ prediction.

However, investors were surprisingly upbeat on Pfizer’s sales prediction from its COVID-19 vaccines in 2021, as the company disclosed that it expected the vaccines to generate around $15 billion in 2021. Stock experts had earlier anticipated that it would earn $12.7 billion in 2021.

Pfizer’s most recent result revealed that the fourth-quarter adjusted diluted earnings per share of 42 cents, below the 50 cents analysts expected.

RelatedPosts

Is the sell off over? U.S stocks snap 8 week losing streak as bulls return

US stock market top gainers for the third week in May

READ: Covid-19: Less than 20,000 vaccines administered in Africa so far – UN

Revenues for the fourth quarter were $11.7 billion, just above the FactSet consensus of $11.5 billion.

Frank D’Amelio, Chief Financial Officer and Executive Vice President, Global Supply, stated:

  • “I am very pleased with how our company performed in 2020, and particularly in the fourth quarter, where we achieved double-digit operational revenue growth driven by a wide range of products and geographies, including growth within all of our therapeutic areas.
  • “I was also pleased that Pfizer completed the transaction to combine Upjohn with Mylan to form Viatris in the fourth quarter, which I believe positions both Pfizer and Viatris for a bright future.
  • “I feel confident in our ability to continue to perform well and deliver on our commitments in 2021 and beyond, both to our patients and to our shareholders.
  • “The company is working round the clock in order to deliver two billion doses of the vaccine this year alone at a breakneck pace as nations rush to sign supply deals in an effort to control the worst pandemic seen in humanity taking to account it had killed over 2 million people globally.”

READ: COVID-19: Pfizer’s vaccine shipments begin in the US

Edward Jones analyst, Ashtyn Evans, told Reuters, “2021 earnings and sales will see a significant benefit from the vaccine, and this benefit could increase throughout the year.”

Pfizer also revealed it had supplied 65 million doses worldwide and 29 million doses in the world’s largest economy, the US, as of Jan. 31. It expects to supply 200 million doses to the U.S. government by the end of May.

Its biggest contracts so far have charged countries around $19 per dose. Pfizer and BioNTech split the gross profit from the vaccine by half under their partnership agreement.

At the time of writing this report, Pfizer shares were down 2.63%, trading at $34.86 at the New York Stock exchange, as investors, pulled back some of their long positions.

Related

Tags: BioNTechCovid-19 vaccineFrank D’AmelioNew York Stock ExchangePfizer

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Mega Millions
Hot forex
Cornerstone
Polaris Bank
Access Bank
Bankers Committee
First bank


FCMB




    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • TrustBanc raises N5.85bn from Series 7 and 8 Commercial Papers; Issue Achieves 117% subscription
    • FIRS extends deadline for filing of 2022 Companies Income Tax returns to 31st August 2022
    • Lagos state government shuts down Redeemers School over death of pupil

    Follow us on social media:

    Recent News

    TrustBanc pays N4.2bn Commercial Paper proceeds at maturity

    TrustBanc raises N5.85bn from Series 7 and 8 Commercial Papers; Issue Achieves 117% subscription

    July 4, 2022
    FIRS calls for comprehensive revenue aggregation

    FIRS extends deadline for filing of 2022 Companies Income Tax returns to 31st August 2022

    July 4, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Financial Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Metrics
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
      • Securities
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
      • Real Estate and Construction
      • Tech News
    • Economy
      • Get Data
      • Macro-Economic News
      • Research Analysis
    • Business News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com